Type IV galactosemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Galactose mutarotase deficiency as the galactosemia type IV.Journal of human genetics · 2025
   Review
2. Clinical and biochemical evolution after partial dietary liberalization of two cases of galactosemia due to galactose mutarotase deficiency.BMC pediatrics · 2024
   Article
3. The Importance of Neonatal Screening for Galactosemia.Nutrients · 2022
   Review
4. Two siblings with galactose mutarotase deficiency: Clinical differences.JIMD reports · 2022
   Article
5. The Discovery of GALM Deficiency (Type IV Galactosemia) and Newborn Screening System for Galactosemia in Japan.International journal of neonatal screening · 2021
   Review
6. Galactosemia: Towards Pharmacological Chaperones.Journal of personalized medicine · 2021
   Review
7. Therapeutic Monosaccharides: Looking Back, Moving Forward.Biochemistry · 2020
   Review

Corrections and comments

• Comment on
  Biallelic GALM pathogenic variants cause a novel type of galactosemia.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as